z-logo
open-access-imgOpen Access
Sestrin-2, a repressor of PDGFRβ signalling, promotes cigarette-smoke-induced pulmonary emphysema in mice and is upregulated in individuals with COPD
Author(s) -
Juliana Heidler,
Athanasios Fysikopoulos,
Frank Wempe,
Michael Seimetz,
Thorsten Bangsow,
Ana Tomasovic,
Florian Veit,
Susan Scheibe,
Alexandra Pichl,
Friederike C. Weisel,
K. C. Kent Lloyd,
Péter Jaksch,
Walter Klepetko,
Norbert Weißmann,
Harald von Melchner
Publication year - 2013
Publication title -
disease models and mechanisms
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.327
H-Index - 83
eISSN - 1754-8411
pISSN - 1754-8403
DOI - 10.1242/dmm.013482
Subject(s) - downregulation and upregulation , copd , repressor , cigarette smoke , signalling , microbiology and biotechnology , pulmonary emphysema , pulmonary disease , medicine , cancer research , chemistry , biology , lung , gene , gene expression , environmental health , genetics
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. COPD is caused by chronic exposure to cigarette smoke and/or other environmental pollutants that are believed to induce reactive oxygen species (ROS) that gradually disrupt signalling pathways responsible for maintaining lung integrity. Here we identify the antioxidant protein sestrin-2 (SESN2) as a repressor of PDGFRβ signalling, and PDGFRβ signalling as an upstream regulator of alveolar maintenance programmes. In mice, the mutational inactivation of Sesn2 prevents the development of cigarette-smoke-induced pulmonary emphysema by upregulating PDGFRβ expression via a selective accumulation of intracellular superoxide anions (O2(-)). We also show that SESN2 is overexpressed and PDGFRβ downregulated in the emphysematous lungs of individuals with COPD and to a lesser extent in human lungs of habitual smokers without COPD, implicating a negative SESN2-PDGFRβ interrelationship in the pathogenesis of COPD. Taken together, our results imply that SESN2 could serve as both a biomarker and as a drug target in the clinical management of COPD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom